Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
190 hedge funds and large institutions have $2.69B invested in Sage Therapeutics in 2017 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 71 reducing their positions, and 15 closing their positions.
207% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 15
43% more capital invested
Capital invested by funds: $1.88B → $2.69B (+$815M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
14% more funds holding
Funds holding: 166 → 190 (+24)
2.79% more ownership
Funds ownership: 98.83% → 101.61% (+2.8%)
28% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 71
63% less call options, than puts
Call options by funds: $53.6M | Put options by funds: $145M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$166M |
| 2 |
Bank of New York Mellon
New York
|
+$78.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$29M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$17M |
| 3 |
Millennium Management
New York
|
-$15.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.2M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$14M |
SAGE Hedge Fund Activity: Q1 2017 in Review
190 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2017, worth a combined $2.69B — up 43% from $1.88B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new SAGE positions and 15 closed out — a net gain of 31 holders — while 51 added to existing stakes and 71 trimmed.
The largest buyer was BlackRock, adding an estimated $166M. The largest seller was Franklin Resources, cutting an estimated $29M.
- 190 institutional investors held Sage Therapeutics (SAGE) as of Q1 2017, up from 166 in Q4 2016.
- Funds reported $2.69B of Sage Therapeutics stock for Q1 2017, up 43% quarter-over-quarter.
- 46 funds opened new Sage Therapeutics positions in Q1 2017 and 15 closed out, a net change of +31 holders.
- The largest Sage Therapeutics buyer in Q1 2017 was BlackRock, an estimated $166M added.
- The largest Sage Therapeutics seller in Q1 2017 was Franklin Resources, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2017.